At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 647 enrolled
Drug / intervention
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed +1 morebiological
Likely dose
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed 0.5 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison in US Adolescents of the Safety and Immunogenicity of Two Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis (Tdap) Vaccines: ADACEL™ and BOOSTRIX®
In Brief
A Phase 4 clinical trial evaluating ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed and BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed for Pertussis and 2 related conditions. Completed, enrolled 647 participants across 10 sites.
Detailed Summary
This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPertussis, Tetanus, Diphtheria
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartMay 2006
Primary CompletionOct 2008
Study CompletionDec 2008
TodayJul 2026
First PostedApr 27, 2006
Enrollment StartMay 1, 2006
Primary CompletionOct 1, 2008
Study CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 20.2 years ago
Interventions
ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbedbiological
0.5 mL, IM
BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbedbiological
0.5 mL, IM